Loading clinical trials...
Loading clinical trials...
The purpose of this study in patients with mucopolysaccharidosis type II (MPS II) is below, * to collect the safety information of JR-141 * to evaluate the plasma pharmacokinetics of JR-141 * to expl...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
JCR Pharmaceuticals Co., Ltd.
NCT02254863 · Adrenoleukodystrophy, Batten Disease, and more
NCT04348136 · Mucopolysaccharidosis II
NCT05422482 · Mucopolysaccharidosis II, Hunter Syndrome
NCT06333041 · Sanfilippo Syndrome, Mucopolysaccharidosis III
NCT05523206 · Mucopolysaccharidosis III-A
Gifu Clinical site
Gifu
Fukuoka Clinical site
Kurume
Tokyo clinical site1
Minato
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions